Cholinesterase inhibitor treatment in patients with delirium [2]

The Lancet

Volumn 377, Issue 9769, 2011, Pages 899-

  De Pont, Anne Cornélie J M ^a   Van Geer, Michael A ^a   Schultz, Marcus J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; HALOPERIDOL; INTERLEUKIN 6; RIVASTIGMINE; TUMOR NECROSIS FACTOR ALPHA; CARBAMIC ACID DERIVATIVE;

CRITICAL ILLNESS; CYTOKINE PRODUCTION; DELIRIUM; DRUG EFFICACY; EMERGENCY CARE; HEALTH STATUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTENSIVE CARE; LETTER; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; AGED; IMMUNOLOGY; NOTE;

AGED; CHOLINESTERASE INHIBITORS; CRITICAL ILLNESS; DELIRIUM; HUMANS; PHENYLCARBAMATES;

EID: 79952463461     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60342-5     Document Type: Letter

References (4)

1. Van Eijk MMJ, Roes KCB, Honing MLH, et al. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind placebo-controlled randomised trial. Lancet 2010; 376: 1829-37.
2. Cerejeira J, Firmino H, Vaz Serra A, et al. The neuroinflammatory pathway of delirium. Acta Neuropathol 2010; 119: 737-54.
3. Van der Poll T, Opal S. Host pathogen interactions in sepsis. Lancet Infect Dis 2008; 8: 32-43.
4. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-33. (Pubitemid 28138465)